RDGT vs SXTC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Despite a stable Piotroski F-Score of 6/9, RDGT is in a state of catastrophic financial and market collapse. The stock has plummeted from a 52-week high of $760.50 to $2.23, representing a near-total loss of value across all timeframes. Most critically, the provided earnings data is over a decade old (dating back to 2011), suggesting a complete failure in current financial reporting and transparency. The combination of negative revenue growth and a 0/100 technical trend indicates a terminal decline.
SXTC presents a profile of a company in a catastrophic financial death spiral, despite a Piotroski F-Score of 5/9 suggesting baseline stability. The stock has collapsed from a 52-week high of $1047.00 to $2.06, representing a near-total loss of shareholder value. While the balance sheet shows low debt and high liquidity (Current Ratio 4.37), the operational reality is dire with an operating margin of -1011.69% and declining revenues. The extreme Price-to-Book ratio of 0.08 indicates the market has almost entirely discounted the company's asset value.
Compare Another Pair
Related Comparisons
RDGT vs SXTC: Head-to-Head Comparison
This page compares Ridgetech, Inc. (RDGT) and China SXT Pharmaceuticals, Inc. (SXTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.